cannabis Related Content

Here, Evolve Ltd’s Managing Director, Christopher Busuttil Delbridge, takes us progressively deeper into what it takes to ensure regulatory compliance for Medical Cannabis.

CBD oil is popular for its wide-ranging therapeutic benefits, but what about its effects on ADHD? Here’s what the research shows.

Kevin William Simpson, CEO and Founder of OilsBySimpson, tells us about the growing evidence around cannabis as a treatment for COVID-19.

Lead Scientific Officer at Always Pure Organics Andrew Megahy, explains how the UK is now in a prime position for the future of CBD use, due to the Novel Foods Application.

Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains the potential of CBD and cannabinoids for skin care.

David Hardstaff of BCL’s Cannabis Law & Regulatory team considers the success of the UK’s legalisation of medicinal cannabis products.

Rick Brar, CEO & Chairman of Brains Bioceutical Corp. explores the landscape of medical cannabis in the UK and the future direction of the industry.

Read on to find out more about Oils By Simpson, Kim Schleppegrell Skaue, and their joint mission to encourage natural medicine use worldwide.

Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains why hemp protein is gaining a reputation as nutraceutical product.

Elixinol, Merges Water-Soluble Technology with THC-Free CBD in a New Range of CBD Blended Tinctures.

Andreas Met, COO, Compliance and Director at Halo Labs highlights how the use of medical cannabis is on the rise in the UK and could offer relief to many NHS patients.

Dr Charlie Easmon from Your Excellent Health Service gives a medical professional’s opinion on medical marijuana in the UK, including comment on hemp, CBD and THC.

Here, Robin Emerson, Head of CSR at Brains Bioceutical charts the priorities for cannabis research.

Professor Mike Barnes, Co-Founder of Maple Tree Consultancy states that the UK’s clinicians need training in medical cannabis and explains precisely why this should be.

Hannah Deacon, Co-Founder of Maple Tree Consultancy and Campaigner ponders if the UK’s post-COVID-19 economy can benefit from a booming medical cannabis industry.

OCD symptoms could be eased by atleast half in the short-term, according to a new study published in the Journal of Affective Disorders.

Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.

In early 2016, I had reached a point in life where I needed to make a life-changing decision: Read the Savage Cabbage journey on OAG.

Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.

CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.